Drug search by name

Dilantin and Liver disease

Result of checking the interaction of drug Dilantin and disease Liver disease for safety when used together.

Check result:

Dilantin <> Liver disease

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Hydantoin anticonvulsants are primarily metabolized by the liver. Both metabolic activity and plasma protein binding may be significantly altered in patients with liver disease, resulting in elevated drug levels (total and unbound fraction) and increased risk of toxicity. Therapy with hydantoin anticonvulsants should be administered cautiously in patients with impaired hepatic function. Reduced dosages and slower titration may be necessary. In addition, periodic monitoring of liver function is recommended, since the use of anticonvulsants, including hydantoins, has been associated with hepatotoxicity related to drug hypersensitivity. Hepatic failure and death have occurred. Hydantoin therapy should be discontinued and not readministered if evidence of liver damage is observed and felt to be drug-related.

References:

"Product Information. Dilantin (phenytoin)." Parke-Davis, Morris Plains, NJ.
"Product Information. Cerebyx (fosphenytoin)." Parke-Davis, Morris Plains, NJ.
Browne TR, Kugler AR, Eldon MA "Pharmacology and pharmacokinetics of fosphenytoin." Neurology 46 (6 supp (1996): s3-7
Olsen GD, Bennett WM, Porter GA "Morphine and phenytoin binding to plasma proteins in renal and hepatic failure." Clin Pharmacol Ther 17 (1975): 677-84
Taylor JW, Stein MN, Murphy MJ, Mitros FA "Cholestatic liver dysfunction after long-term phenytoin therapy." Arch Neurol 41 (1984): 500-1
Roy AK, Mahoney HC, Levine RA "Phenytoin-induced chronic hepatitis." Dig Dis Sci 38 (1993): 740-3
Prosser TR, Lander RD "Phenytoin-induced hypersensitivity reactions." Clin Pharm 6 (1987): 728-34
Egerton-Vernon JM, Fisk MJ, Snell AP "Phenytoin-induced hepatotoxicity." N Z Med J 96 (1983): 467-9
Sherertz EF, Jegasothy BV, Lazarus GS "Phenytoin hypersensitivity reaction presenting with toxic epidermal necrolysis and severe hepatitis." J Am Acad Dermatol 12 (1985): 178-81
Hooper WD, Bochner F, Eadie MJ, Tyrer JH "Plasma protein binding of diphenylhydantoin: effects of sex hormones, renal and hepatic disease." Clin Pharmacol Ther 15 (1974): 276-82
Aaron JS, Bank S, Ackert G "Diphenylhydantoin-induced hepatotoxicity." Am J Gastroenterol 80 (1985): 200-2
"Product Information. Mesantoin (mephenytoin)" Novartis Pharmaceuticals, East Hanover, NJ.
Mullick FG, Ishak KG "Hepatic injury associated with diphenylhydantoin therapy: a clinicopathologic study of 20 cases." Am J Clin Pathol 74 (1980): 442-52
"Product Information. Peganone (ethotoin)" Abbott Pharmaceutical, Abbott Park, IL.
Gennis MA, Vemuri R, Burns EA, et al "Familial occurrence of hypersensitivity to phenytoin." Am J Med 91 (1991): 631-4
Korman LB, Olson MJ "Phenytoin-induced hepatitis, rhabdomyolysis, and renal dysfunction." Clin Pharm 8 (1989): 514-5
Affrime M, Reidenberg MM "The protein binding of some drugs in plasma from patients with alcoholic liver disease." Eur J Clin Pharmacol 8 (1975): 267-9